Patents
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2002
06/05/2002EP1210455A1 Novel glycosyl sulfotransferases gst-4 alpha, gst-4 beta, and gst-6
06/05/2002EP1210435A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
06/05/2002EP1210434A2 Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
06/05/2002EP1210429A2 Apoptosis proteins
06/05/2002EP1210428A1 Pd-1, a receptor for b7-4, and uses therefor
06/05/2002EP1210425A2 Baff receptor (bcma), an immunoregulatory agent
06/05/2002EP1210422A2 Human abc2 transporter and uses thereof
06/05/2002EP1210419A2 Human transmembrane proteins
06/05/2002EP1210370A1 Human tumor necrosis factor receptor tr16
06/05/2002EP1210354A1 Prodrugs for liver specific drug delivery
06/05/2002EP1210350A1 Water soluble sdz-rad esters
06/05/2002EP1210348A1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
06/05/2002EP1210344A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
06/05/2002EP1210341A1 Compositions and therapeutic methods involving isoflavones and analogues thereof
06/05/2002EP1210335A1 Aminocarbonyl-substituted benzimidazole derivatives, method for producing same and the use thereof as medicaments
06/05/2002EP1210327A2 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments
06/05/2002EP1210326A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
06/05/2002EP1210325A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
06/05/2002EP1210320A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
06/05/2002EP1210121A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
06/05/2002EP1210119A1 Pharmaceutical compositions for oral and topical administration
06/05/2002EP1210110A1 Prion protein binding proteins and uses thereof
06/05/2002EP1210104A1 Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
06/05/2002EP1210100A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins
06/05/2002EP1210099A1 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras
06/05/2002EP1210087A2 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
06/05/2002EP1210079A2 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
06/05/2002EP1210065A1 Cationic liposome delivery of taxanes to angiogenic blood vessels
06/05/2002EP1210063A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents
06/05/2002EP1137438B1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/05/2002EP0966430B1 Anti-inflammatory compounds
06/05/2002EP0888337B1 Piperidone tachykinin antagonists
06/05/2002EP0804228B1 Medicament containing protein C activation peptide
06/05/2002EP0711282B1 Compounds as pde iv and tnf inhibitors
06/05/2002EP0642516B1 Macrocyclic immunomodulators
06/05/2002CN1352691A Human complement C3-degrading polypeptide from i(streptococcus pneumoniae)
06/05/2002CN1352686A Cytokine receptor chain
06/05/2002CN1352636A Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
06/05/2002CN1352568A Water soluble compositions for bioactive lipophilic compounds
06/05/2002CN1352563A Use of phyllanthus for targeted stimulation of the immune system
06/05/2002CN1352545A 吲哚衍生物 Indole derivatives
06/05/2002CN1351880A Pus drawing out paste for expelling wind and removing obstruction in channels and its preparing method
06/05/2002CN1351871A Compound chlorhexidine cream and its prepairng method
06/05/2002CN1085947C Powder prepared with colophony, realgar and Huangdan
06/05/2002CA2327631A1 Inflammatory cytokine secretion inhibition
06/04/2002US6399797 Vitamin D analogues
06/04/2002US6399780 Kinase inhibitors; anticancer agents
06/04/2002US6399773 Autoimmune disease; transplanting organs
06/04/2002US6399657 Antiinflammatory agents
06/04/2002US6399656 Using a benzopyran-3-carboxamide compound
06/04/2002US6399648 N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
06/04/2002US6399643 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom
06/04/2002US6399636 For therapy of asthma, chronic bronchitis, chronic obstructive pulmonary disease (copd), eosinophilic granuloma, psoriasis and septic shock, ulcerative colitis, crohn's disease, reperfusion injury of the myocardium and brain
06/04/2002US6399635 N,n-diethyl-4-(n-piperidin-3-yl-anilino) benzamide compound; reductive amination of a 3-piperidone, arylation
06/04/2002US6399626 Useful in inducing immunosuppression and in treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, vascular disease
06/04/2002US6399625 1-oxorapamycins
06/04/2002US6399620 Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists
06/04/2002US6399611 2-(4-ethoxycarbonylaminobenzyl)-6-(3,4 -dimethoxyphenyl)-2,3,4, 5-tetrahydropyridazin-3-one or alternately benzyl substituted compounds; phosphodiesterase iv and tumour necrosis factor inhibitors
06/04/2002US6399573 Interleukin-1 receptor antagonist beta (IL-1rabeta)
06/04/2002US6399572 Administering antithrombin
06/04/2002US6399376 Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
06/04/2002US6399297 Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
06/04/2002US6399139 Controlling material handling
06/04/2002US6399095 Aloe leaves, freeze drying and vacuum drying
06/04/2002US6399079 Spill resistant pharmaceutical compositions in semi-solid form
06/04/2002US6399053 Methods of enhancing bioactivity of chemokines
06/04/2002CA2302396C Allosteric adenosine receptor modulators
05/2002
05/30/2002WO2002042777A2 Modulation of the interaction between evh1 domains
05/30/2002WO2002042333A1 Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
05/30/2002WO2002042332A2 Truncated cd200
05/30/2002WO2002042319A2 2-substituted estrogens as antiangiogenic agents
05/30/2002WO2002042306A1 Benzimidazole derivatives, preparation and therapeutic use thereof
05/30/2002WO2002042303A2 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
05/30/2002WO2002042302A1 Novel sulfonamide-substituted pyrazolopyridine derivatives
05/30/2002WO2002042301A1 Novel pyridine-substituted pyrazolopyridine derivatives
05/30/2002WO2002042300A1 Novel carbamate-substituted pyrazolopyridine derivatives
05/30/2002WO2002042299A1 Novel lactame-substituted pyrazolopyridine derivatives
05/30/2002WO2002042298A1 Aminothiazoles and their use as adenosine receptor antagonists
05/30/2002WO2002042296A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives
05/30/2002WO2002042292A2 Indol derivative and their use as inhibitors of p38 kinase
05/30/2002WO2002042280A2 Pyrimidine derivatives
05/30/2002WO2002042278A2 Imidazole and benzimidazole caspase inhibitors and uses thereof
05/30/2002WO2002042273A2 Acid derivatives useful as serine protease inhibitors
05/30/2002WO2002042269A1 3-arylindole derivatives and their use as cb2 receptor agonists
05/30/2002WO2002042257A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases
05/30/2002WO2002042248A2 Naphthalene derivatives
05/30/2002WO2002041915A1 A composition of sodium channel blocking compound
05/30/2002WO2002041912A1 Drugs and foods improving the quality of life and process for producing the same
05/30/2002WO2002041882A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
05/30/2002WO2002041843A2 Antiinflammation agents
05/30/2002WO2002041837A2 Treatment of mucositis
05/30/2002WO2002041831A2 Inositol derivatives for increasing chloride secretion and inhibiting inflammation
05/30/2002WO2002022599A3 Chemokine receptor binding heterocyclic compounds
05/30/2002WO2002020736A9 Proteases
05/30/2002WO2002002565A3 Glucocortiocoid-selective antiinflammatory agents
05/30/2002WO2002000611A3 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/30/2002WO2001098270A3 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
05/30/2002WO2001097775A3 Controlled release anti-inflammatory formulation
05/30/2002WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
05/30/2002WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription